Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DaVitaDVA +1.19%88 9-Day RSI is 76.97 as of Jul. 13, 2026. GuruFocus rates DVA with a GF Score™ of 88/100 and a GF Value™ of $174.66 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 697 Healthcare Providers & Services companies, DaVita ranks worse than 93.4% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-13), DaVita's 9-Day RSI is 76.97.
The industry rank for DaVita's 9-Day RSI or its related term are showing as below:
DVA's 9-Day RSI is ranked worse than 93.4% of 697
companies
in the Healthcare Providers & Services industry
Industry Median: 51.99
vs DVA: 76.97
DaVita (NYSE:DVA) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
DaVita 9-Day RSI Related Terms
DVA vs THC, EHC, ENSG: 9-Day RSI Comparison
For the Medical Care Facilities subindustry, DaVita's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DaVita 9-Day RSI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DaVita's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where DaVita's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DaVita (DVA) has a 9-Day RSI of 76.97 as of Jul. 13, 2026. According to the industry distribution chart, DaVita ranks #651 out of 697 companies in the Healthcare Providers & Services industry, placing it in the top 93.4%.
Is DaVita's 9-Day RSI too high?
DaVita's current 9-Day RSI is 76.97. The Healthcare Providers & Services industry median 9-Day RSI is 51.99. DaVita's value of 76.97 is 48% above this industry median. Based on the distribution chart, DaVita ranks #651 out of 697 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, DaVita has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does DaVita's 9-Day RSI compare to THC and EHC?
According to the Healthcare Providers & Services industry distribution chart, DaVita ranks #651 out of 697 companies for 9-Day RSI. This places DaVita in the lower half of its industry. The industry median 9-Day RSI is 51.99. DaVita's value of 76.97 is 48% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Healthcare Providers & Services company?
The median 9-Day RSI among Healthcare Providers & Services companies is 51.99, based on 697 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DaVita's current 9-Day RSI of 76.97 is 48% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median 9-Day RSI is 51.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DaVita's current 9-Day RSI is 76.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DaVita stock overvalued right now?
Based on GuruFocus' analysis, DaVita (DVA) is currently considered Significantly Overvalued. The stock's GF Value™ is $174.66, compared to a current price of $235.58 — trading 34.9% above its estimated fair value. The current 9-Day RSI is 76.97 and 48% above the Healthcare Providers & Services industry median of 51.99. DaVita's overall GF Score™ is 88/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For DaVita (DVA), the current 9-Day RSI is 76.97 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DaVita (DVA) Overvalued in 2026?
Based on GuruFocus' analysis, DaVita stock appears to be overvalued.
The current stock price of $235.58 is trading 34.9% above its estimated GF Value™ of $174.66.
GuruFocus considers DaVita to be Significantly Overvalued.
Key valuation signals for DVA:
9-Day RSI: 76.97
GF Value™: $174.66 vs. price of $235.58 (34.9% above fair value)
Industry Position: 48% above the Healthcare Providers & Services median (#651 of 697)
No single metric tells the full story. See the DVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
88GF Score
Get the complete analysis for DVA
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DVA has been successfully added to your 
